Biomolecules can experience aging processes that limit their long-term functionality in organisms. Typical markers of protein aging are spontaneous chemical modifications, such as AAR (amino acid racemization) and AAI (amino acid isomerization), mainly involving aspartate and asparagine residues. Since these modifications may affect folding and turnover, they reduce protein functionality over time and may be linked to pathological conditions. The present mini-review describes evidence of AAR and AAI involvement in the misfolding and brain accumulation of Aβ (amyloid β-peptide), a central event in AD (Alzheimer's disease) synaptic dysfunctions. Structural alterations introduced by site-specific modifications linked to protein aging may affect Aβ production, polymerization and clearance, and therefore play a pivotal role in the pathogenesis of sporadic and genetic forms of AD. Early changes associated with molecular aging also have significant long-term consequences for Aβ folding and turnover. New fast, reproducible and accurate methods for the screening of protein aging markers in biological samples may contribute to improve diagnostic and therapeutic approaches in AD.
glycine, exclusively L-amino acids are incorporated during protein synthesis. Racemization, the progressive spontaneous conversion of L-into D-enantiomers, is an example of agerelated damage.
The turnover rate of proteins is an important factor in determining whether aging has a significant effect. Damage in proteins with a high turnover, such as intracellular proteins, is not particularly dangerous, because newly synthesized molecules quickly replace the old ones. In contrast, extracellular proteins, in tissues such as skin, bone, cartilage and eye lens accumulate damages over time as they have a lower turnover rate and limited opportunities for repair [2] . Robinson and Robinson [3, 4] suggested that age-related damage may act as a molecular timer to regulate protein catabolism. In this view, degradation may represent an alternative means by which to repair damaged proteins ( Figure 1 ) [5] .
It is conceivable that random spontaneous changes may lead to dramatic chemical modifications in protein sequence and folding [6] , which shield the molecule from the normal clearance and degradation pathways. In this case, modified proteins could begin to accumulate in tissues, increasing the damage effect over time ( Figure 1 ).
Protein aging, through spontaneous modifications of specific amino acid residues, represents a complex process that can control the final destiny of a protein and may be associated with pathological conditions.
AAR (amino acid racemization) and AAI (amino acid isomerization) as markers of protein aging Figure 1 Protein aging chart
The final effect of spontaneous alterations produced by the aging process can vary according to the molecule turnover rate and the availability in the tissue of a repair system.
Whereas the pathways of racemization/isomerization of serine and alanine as peptide-bound residues are still unknown, isomerization and racemization of aspartate and deamidation of asparagine are better characterized and represent the most frequent type of aging-related protein damage. These reactions proceed through the formation of a cyclic succinimide intermediate, which is rapidly converted into stable isoaspartate or D-aspartate residues (Figure 2 ). The succinimide intermediate is a short-lived form, but the presence of an isoaspartate residue in a protein is a direct indication that cyclization of aspartate to succinimide has occurred.
Evidence that aspartate racemization/isomerization is a relevant damage for protein functionality is the existence of a specific repair system, based on the action of PIMT (protein L-isoaspartyl/D-aspartyl methyltransferase). This enzyme is able to recognize isoaspartate residues in polypeptides and regenerates the normal L-aspartate residues ( Figure 2 ) [1, 8] . However, this system is not completely efficient, as the D-isoaspartate residue is not recognized, deamidated Lasparagine can be restored only to the L-aspartate form and the human enzyme preferentially acts on peptides containing L-isoaspartate, rather than D-aspartate residues [9, 10] . Furthermore, this repair system seems to be not equally functional in all the tissues. For example, in the brain, several proteins appear to be particularly prone to asparagine deamidation and aspartate racemization/isomerization. It has been reported that modified aspartate residues dramatically increase with age in proteins expressed in this organ [11] . For brain extracellular proteins, this is essentially a severe and permanent damage, as no mechanism exists to repair isoaspartate outside the cell. Similarly to aspartate and asparagine, glutamate racemization and glutamine deamidation proceed through a cyclic intermediate, but normally with a much lower reaction rate [12] .
Proline isomerization can affect the regulation of metabolic processes, eventually inducing degeneration of the protein into pathological forms. Proline has the unique ability to adopt distinct cis or trans conformations, which allows it to act as a backbone switch. The transition between the two forms is catalysed by the group of peptidylprolyl cistrans isomerase enzymes. In particular, Pin1 (prolyl isomerase 1) binds and isomerizes phosphorylated serine/threonineproline motifs, influencing signalling in diverse cellular processes, through the regulation of the conformation of its substrates [13] .
AAR and AAI represent the major non-enzymatic agedependent covalent modifications affecting protein folding and degradation [2] , and in the present mini-review, we describe the role of these modifications in relation to accumulation of Aβ (amyloid β-peptide) in the brain, a central event in the pathogenesis of AD (Alzheimer's disease).
Markers of protein aging in the brain of AD patients
One of the most well-studied proteins in relation to pathological misfolding is the APP (amyloid precursor protein) and the products of APP processing: Aβ, especially the peptides Aβ 1−35 , Aβ 1−40 and Aβ 1−42 . These peptides, expressed in many biological fluids, accumulate in the brain in fibrillar aggregated forms, characterized by non-native β-sheet structures, and extracellular amyloid plaques, which are hallmark events of AD [14, 15] . They may result from the imbalance between the mechanisms of Aβ production and clearance. Recent studies reveal that multiple assembled forms of Aβ mediate Aβ synaptotoxicity [16] . In AD, cognitive decline correlates with the presence of small aggregates, such as soluble Aβ oligomers and protofibrils, which accumulate in the synapses, producing a dramatic impairment of synaptic plasticity [17, 18] . The aggregation of Aβ is not the only neuropathological event of AD caused by protein misfolding; another example is the polymerization of the microtubuleassociated protein tau into insoluble filaments that aggregate as NFTs (neurofibrillary tangles) [14, 15] .
The identification of the mechanisms that controls Aβ folding and the balance between the Aβ production and clearance is a pivotal step in the comprehension of AD pathogenesis. Although the role of AAR or AAI in these processes is still unclear, evidence of their association with Aβ brain deposition exists in AD: several studies have demonstrated that Aβs isolated from amyloid plaques contain high levels of isomerization and racemization. The accumulation of D-aspartate and isoaspartate is linked to aging, therefore these should be found at higher levels in senile plaques. Moreover, aspartate residues, at positions 1, 7 and 23 of Aβ, may be crucial in the control of Aβ generation and aggregation.
Residues 1 and 7 of Aβ in amyloid plaques are a mixture of L-, D-, L-iso-and D-iso-aspartate, with L-isoaspartate as the predominant form [19] . Roher et al. [20] suggested that these alterations might contribute to the production and stability of β-amyloid deposits in the brain of AD patients. Aβ accumulated in vascular deposits in the brain contains significantly less isomerized and racemized aspartate residues than do amyloid plaques. These data were considered indicative of the different time of formation of the two kinds of Aβ deposits: plaque deposition seems to be older and consequently an earlier pathological event that precedes the formation of vascular deposits in AD [20] .
Most of the subsequent studies, based on the immunodetection of isomerized aspartate residues in senile plaques, noted an additional isoaspartate residue at position 23 of Aβ [21] , but Asp 7 was documented as the main site of modification of Aβ, largely composed of L-isoaspartate [19] . As confirmation that such chemical modifications are strongly connected to Aβ misfolding and deposition in the brain, Iwatsubo et al. [22] found them in diffuse brain plaques of patients with Down's syndrome, another pathology characterized by brain accumulation of amyloid plaques. Mori et al. [23] demonstrated that racemization may occur after amyloid fibril formation in AD, but nevertheless its final effect on Aβ polymerization properties depends on the position of D-isomer incorporation. For example, D-Asp 7 can enhance the aggregation process by shifting the equilibrium of Aβ from the soluble to the insoluble form. Kuo et al. [24] suggested a contribution of isomerization at positions 1 and 7 of Aβ 1−42 in increasing Aβ insolubility and resistance to proteolysis degradation [24] , and Shimizu et al. [21] , which contributes to neurodegeneration. This work suggests a possible connection between amino acid modifications of Aβ and amyloid peptide susceptibility to brain proteases, enzymes that could mediate both the degradation of Aβ toxic forms and the production of dangerous Aβ metabolites.
Further evidence of the role of spontaneous modifications in AD development was found in NFTs from ADaffected brains, which also contained racemized proteins, notably hyperphosphorylated tau that is frequently isomerized/racemized at specific aspartate residues [26, 27] . Proline isomerization seems also to be involved in AD misfolding and neurodegeneration. Pin1 expression is inversely correlated with neurofibrillary degeneration in AD [28] , and Pastorino et al. [29] demonstrated that Pin1 has profound effects on APP processing and Aβ production.
Although it remains unclear whether AAR and AAI are early events of AD pathogenesis or a direct consequence of Aβ misfolding, spontaneous modifications evidently play a key role in the abnormal Aβ deposition and in the development of sporadic AD.
Protein aging and Aβ aggregation
The initial evidence of association between amyloid plaques and markers of protein aging was followed by in vitro studies, in order to better understand the effect of AAR and AAI on Aβ fibrillization. Different research groups compared aggregation properties of synthetic Aβ analogues containing the modifications identified in amyloid plaques (mainly D 23 peptide initially showed a slightly retarded increase in aggregation, followed by a significant increase in rate during the final stage of aggregation. The disagreement between these two sets of findings could be due to the additional five amino acids in the C-terminal portion of the Aβ 1−40 peptide. However, the hypothesis that modifications in Asp 7 may have an early and relevant role in Aβ aggregation is supported by the many findings of racemized and isomerized Asp 7 detected in amyloid plaques from AD brains. Orpiszewski et al. [31] , in 2000, noted the propensity for succinimide formation of Asp 7 , which lies N-terminal to a serine residue, a primary structure known to accelerate the formation of succinimide, that readily undergoes conversion into D-aspartate or isoaspartate [32] .
Sakai-Kato et al. [33] analysed the aggregation properties of The relationship between aggregative ability and neurotoxicity seems to be even more complex. Murakami et al. [34] Altogether, these in vitro studies demonstrate the involvement of products of protein aging, namely aspartate racemization/isomerization, in Aβ polymerization. The consequences of these non-enzymatic modifications are sitespecific and can increase or decrease fibrillization, according to the structural alterations introduced by the site-specific incorporation of modified aspartate residues.
The chemical alterations produced by the aging process of Aβ could play a pivotal role also in genetic forms of AD. The best-known mutations associated with hereditary forms of AD involve the central residues 21, 22 and 23 of Aβ. In particular, the Dutch (E22Q) and Iowa (D23N) mutations present higher aggregation properties and neurotoxicity than the wild-type Aβ. Consequently, these residues seem to have a strong pathogenic role in the deposition of Aβ, being particularly sensitive to modifications, caused either by genetic mutations or by the molecular aging of Aβ. In Iowatype familial cerebral amyloid angiopathies, high levels of Aβ deposits are associated with the presence of IsoAsp 23 [21] and, actually, asparagine condenses to succinimide an order of magnitude more rapidly than aspartate [4, 21] (Figure 2 ). In addition, a similar mutation to asparagine of Asp 7 is linked to an increased formation of isoaspartate and high Aβ deposition in the brain in a form of familial AD [35] .
Protein aging and the balance between Aβ production and clearance
So far, protein-aging events have been considered in terms of their ability to enhance the aggregative properties of Aβ. However, Aβ brain accumulation may also result from the imbalance between production and clearance. Antibodies, microglia, complement system and proteolytic enzymes can normally mediate the elimination of Aβ and reduce the amyloid load in the brain, but their action is often impaired in subjects affected by AD [36, 37] . The activation of enzymes regulating APP processing and Aβ production can also be responsible for the increased Aβ availability for oligomer, fibril and plaque formation. Consequently, protein-aging events, modifying critical APP and Aβ amino acid residues, can be involved directly in controlling this balance.
Aβ is generated when APP is sequentially cleaved by β-and γ -secretases. The first enzyme liberates the N-terminal region of Aβ by the cleavage between Met 671 and Asp 672 of APP, consequently Asp 672 in APP becomes Asp 1 of Aβ. The subsequent cleavage of γ -secretase releases the C-terminal region of Aβ [38, 39] . BACE-1 (β-site APP-cleaving enzyme 1) had been considered for a long time as the β-secretase operating the first step of APP processing towards Aβ generation. However, recent work has demonstrated that more than one β-secretase initiates this cascade: for example, cathepsin B has been shown to be able to operate the cleavage between Met 671 and Asp 672 of APP [40] . The existence of two β-secretases has particular relevance for isoaspartate formation at the β-secretase cleavage site. When isoaspartate is present at position 672, cathepsin B can catalyse the cleavage between Met 671 and IsoAsp 672 with high efficiency. Since spontaneous aspartate isomerization cannot take place readily in a peptide at the N-terminal position ( [41] and M.J. Collins, unpublished work), isoaspartate formation at Aβ position 1 can only occur, as an early event in Aβ production, before β-secretase cleavage. This means that isomerization at position 672 of APP could activate a cascade of events able to increase Aβ production and aggregation.
Furthermore, isoaspartate, rather than aspartate, in the vicinity of a scissile bond may reduce susceptibility to proteolytic degradation [42] . Consequently, when this modification occurs at position 672 of APP, the final result can be the shift of APP processing to release a low-turnover form of Aβ. Accordingly, it emerges that Asp 1 isomerization is a very relevant modification in Aβ, both for its character of early events in AD pathogenesis and for its direct role in Aβ accumulation through the induction of protease resistance.
Other markers of protein aging in amyloid plaques are also associated with a reduced activation of Aβ clearance. For example, microglia were detected around plaques containing both isoaspartate and aspartate at position 7; however, its density and, in some cases, the numbers of reactive microglia around plaques containing isoaspartate were lower [43] , indicating that this modification introduces a route to escape microglia-mediated clearance. Actually, the Aβ region containing amino acids 4-11 is necessary for complement activation [44] , which starts a series of events leading to microglia recruitment and activation around the plaques. In addition, the non-native secondary structures induced by succinimide formation may impair Aβ interactions with immunoglobulin, leading to a reduced antibody-mediated clearance of Aβ [31] .
Protein aging in the control of dangerous Aβ misfolding
The recognition of the role played by site-specific racemization and isomerization events in Aβ misfolding will arguably allow a better understanding of AD pathogenesis and will open new diagnostic and therapeutic perspectives.
The results produced so far highlight the necessity for new, fast and reproducible methods for the detection and accurate identification of isoaspartate in Aβ and aggregated forms. Sophisticated MS-based approaches have recently been introduced successfully for the detection of specific isoaspartate residues in Aβ [45] . This may be a preliminary step for the screening of biological samples of AD patients and considering these modifications as AD biomarkers. As the accumulation of isoaspartate residues reduces the turnover of Aβ deposits, the immunodetection of this modification may be used in the future as indicator of the age of the amyloid plaques [43] .
Examples of future therapeutic strategies based on the modulation of fibrillogenic amino acid modifications could be modulation of isomerization and racemization of Asp 1 , which blocks the increased fibrillization caused by Asp 23 racemization [33] and induces APP processing [41] , or the incorporation of D-amino acid to inhibit the self-association in fibril-forming peptides [46] .
Other approaches to control Aβ aggregation could derive from a better knowledge of specific chemical conditions that enhance both Aβ fibrillization and AAR. For example, recent experimental evidence suggests that the treatment of synthetic Aβ with reactive oxygen species can potentially produce a reliable in vitro model of Aβ misfolding, characterized by increased aggregation and AAR rate over time (M.L. Moro, M.J. Collins and E. Cappellini, unpublished work).
In conclusion, 'aging' has a direct role in AD and not only because it largely involves elderly people. The main AD pathological molecules are themselves affected by aging processes and their consequent misfolding and altered functionality contribute greatly to the disease. Since the aging of biomolecules takes place much earlier than signals of general aging in a human individual emerge, the study of makers of protein aging may represent a future way to early diagnose and prevent the progress of AD.
